Do amyloid-lowering strategies work clinically?

Aisen, P.S. , Saumier, D. , Briand, R. , Laurin, J. , Gervais, F. , Tremblay, P. , et al. (2006) A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease Neurology 67: 1757-1763. Epub 2006 Nov 2.

Bertram, L. and Tanzi, R.E. (2008) Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses Nat Rev Neurosci 10: 768-778.

Doody, R.S. , Gavrilova, S.I. , Sano, M. , Thomas, R.G. , Aisen, P.S. , Bachurin, S.O. et al. (2008) Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study . Lancet 372: 207-215.

Dubois, B. , Feldman, H.H. , Jacova, C. , Dekosky, S.T. , Barberger-Gateau, P. , Cummings, J. et al. (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria Lancet Neurol 6: 734-746.

Fox, N.C. , Black, R.S. , Gilman, S. , Rossor, M.N. , Griffith, S.G. , Jenkins, L. et al. (2005) Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease Neurology 64: 1563-1572.

Gilman, S. , Koller, M. , Black, R.S. , Jenkins, L. , Griffith, S.G. , Fox, N.C. et al. AN1792(QS-21)-201 Study Team., (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562.

Gura, T. (2008) Hope in Alzheimer's fight emerges from unexpected places Nat Med 14: 894.

Hardy, J.A. and Higgins, G.A. (1992) Alzheimer's disease: the amyloid cascade hypothesis Science 256: 184-185.

Hardy, J. and Selkoe, D.J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297: 353-356.

Heneka, M.T. and Landreth, G.E. (2007) PPARs in the brain Biochim Biophys Acta 1771: 1031-1045. Epub 2007 May 10.

Holmes, C. , Boche, D. , Wilkinson, D. , Yadegarfar, G. , Hopkins, V. , Bayer, A. et al. (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial Lancet 372: 216-223.

Kulstad, J.J. , Green, P.S. , Cook, D.G. , Kahn, S.E. , Keeling, M.L. and Craft, S. (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study Am J Geriatr Psychiatry 13: 950-958.

Lannfelt, L. , Blennow, K. , Zetterberg, H. , Batsman, S. , Ames, D. , Harrison, J. et al; PBT2-201-EURO study group. ( 2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised,placebo-controlled trial. Lancet Neurol 7: 779-86. Epub 2008 Jul 30.

Marum, R.J. van. (2008) Current and future therapy in Alzheimer's disease Fundam Clin Pharmaco 22: 265-274.

Rankin, C.A. and Gamblin, T.C. (2008) Assessing the toxicity of tau aggregation J Alzheimers Dis 14: 411-416.

Selkoe, D.J. (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior Behav Brain Res 192: 106-113. Epub 2008 Feb 17.

Watson, G.S. , Cholerton, B.A. , Reger, M.A. , Baker, L.D. , Plymate, S.R. , Asthana, S. et al. (2006) Rosiglitazone in Alzheimer's Disease Study Group. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease Pharmacogenomics J 6: 246-254. Epub 2006 Jan 31.

Wilcock, G.K. , Black, S.E. , Hendrix, S.B. , Zavitz, K.H. , Swabb, E.A. , Laughlin, M.A. et al. (2008) Tarenflurbil Phase II Study investigators. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial Lancet Neurol 7: 483-493. Epub 2008 Apr 29.